Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
09 déc. 2024 15h42 HE
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial
09 déc. 2024 08h45 HE
|
Sonnet BioTherapeutics Holdings, Inc.
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level Stable disease (SD) at four months...
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment
12 nov. 2024 09h15 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug...
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
06 nov. 2024 13h20 HE
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing innovative targeted...
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates
06 nov. 2024 08h30 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18...
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq
17 oct. 2024 08h45 HE
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic...
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India
09 oct. 2024 08h45 HE
|
Sonnet BioTherapeutics Holdings, Inc.
Sonnet to receive $1.0 million in upfront payment and up to an additional$1.0 million in milestone payments with a royalty in the low double digits on net sales, less certain expenses, in the India...
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
30 sept. 2024 09h00 HE
|
Sonnet BioTherapeutics Holdings, Inc.
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Provides interested parties the ability to ask questions and submit...
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
25 sept. 2024 08h30 HE
|
Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted...
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 sept. 2024 08h30 HE
|
Sonnet BioTherapeutics Holdings, Inc.
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE...